Revolution Medicines (RVMD) Operating Expenses (2019 - 2026)

Revolution Medicines has reported Operating Expenses for 8 years, with the latest figure at $445.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 84.92% year-over-year to $445.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 75.68% YoY), and the FY2025 full-year result was $1.2 billion, up 71.48% from the prior year.
• Operating Expenses for Q1 2026 stood at $445.2 million, up from $361.6 million in the prior quarter.
• The five-year high for Operating Expenses was $445.2 million in Q1 2026, with the low at $65.5 million in Q1 2022.
• Average Operating Expenses over 5 years is $182.9 million, with a median of $156.6 million recorded in 2024.
• Year-over-year, Operating Expenses soared 134.6% in 2023 and advanced 19.69% in 2024.
• Tracing RVMD's Operating Expenses over 5 years: stood at $77.0 million in 2022, then soared by 134.6% to $180.7 million in 2023, then rose by 19.69% to $216.3 million in 2024, then surged by 67.18% to $361.6 million in 2025, then increased by 23.12% to $445.2 million in 2026.
• The last three Operating Expenses figures came in at $445.2 million (Q1 2026), $361.6 million (Q4 2025), and $315.3 million (Q3 2025), per Business Quant data.

Peer Comparison